novo nordisk wegovy - Search News

News

Wegovy, Novo Nordisk and Food and Drug Administration

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly ,

The Wall Street Journal on MSN · 21h

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded versions of the drug.

CNBC on MSN · 22h

Novo Nordisk's Wegovy weight loss drug sales soar 67% in second quarter

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from compounded drug makers. The pharma giant last week cut its full-year guidance and named Mike Doustdar as its new CEO.

17h

Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

5hon MSN

Why Novo Nordisk Stock Slipped Today

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

Marketplace14h

Makers of Wegovy, Zepbound face competition from compounding pharmacies

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

5don MSN

Novo Nordisk shares dip further as Wegovy gains nearly erased

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results